TKM Ebola

TKM-Ebola (synonym Ebola-SNALP ) is an experimental drug from the group of RNAi therapeutics against the Ebola virus .

properties

TKM-Ebola is a mixture of siRNA on liposomes , which after application leads to an in vivo transfection in which the RNA is taken up in cells. The RNA binds to the genome of Ebola viruses and triggers RNA interference against these sequences. TKM-Ebola was developed by Tekmira Pharmaceuticals Corp. developed. A phase I study was started in January 2014, but was classified as on hold by the Food and Drug Administration in July 2014 and was interrupted because subjects developed flu-like symptoms. In August 2014, the status was changed to on partial hold , which allows use under compassionate use conditions. In 2015, the TKM-Ebola clinical trial at Port Loko was canceled due to a lack of efficacy attributed to the older version of the vaccine formulation and study design.

Individual evidence

1. ↑ David Kroll: FDA Moves On Tekmira's Ebola Drug While Sarepta's Sits Unused . In: Forbes , 7 August 2014.
2. ↑ Cynthia Koons, Caroline Chen, Robert Langreth: Ebola Drug by Tekmira May Be Used on Infected Patients . In: Bloomberg News , August 8, 2014.
3. ↑ Gretchen Vogel, Kai Kupferschmidt: In setback for potential Ebola drug, company halts trial . In: Science , June 19, 2015.

This article is about a health issue. It is not used for self-diagnosis and does not replace a diagnosis by a doctor. Please note the information on health issues !